Nicox (LTS:0RCQ) Interest Expense : €-1.94 Mil (TTM As of Jun. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Nicox Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Nicox's interest expense for the six months ended in Jun. 2024 was € -1.12 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2024 was €-1.94 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Nicox's Operating Income for the six months ended in Jun. 2024 was € -3.42 Mil. Nicox's Interest Expense for the six months ended in Jun. 2024 was € -1.12 Mil. Nicox did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Nicox Interest Expense Historical Data

The historical data trend for Nicox's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Interest Expense Chart

Nicox Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

0.87

-2.21

-2.02

-1.63

Nicox Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Interest Expense	Get a 7-Day Free Trial															-0.89	-0.74	-0.82	-0.81	-1.12

Nicox Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-1.94 Mil.

Nicox (LTS:0RCQ) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Nicox's Interest Expense for the six months ended in Jun. 2024 was €-1.12 Mil. Its Operating Income for the six months ended in Jun. 2024 was €-3.42 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2024 was €20.01 Mil.

Nicox's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as

Nicox did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Nicox Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (LTS:0RCQ) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

NICXF:USA ALCOX:France NXOA:Germany

Address

Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410

Website

https://www.nicox.com

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.

Nicox Headlines

No Headlines